AMRX Amneal Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1723128 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY2,159.3%
TTM EPS YoY3,900.0%
Revenue 3-yr CAGR10.2%
Net income 3-yr CAGR270.1%
Margins
Gross margin40.2%
Operating margin15.0%
Net margin4.2%
FCF margin2.8%
EBITDA margin—
Returns
ROE63.2%
ROA3.0%
ROIC (approx.)16.3%
Asset turnover0.72x
Leverage & solvency
Liabilities / assets87.8%
Debt / equity5.53x
Current ratio1.87x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.36x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.02B | $2.79B |
| Cost of revenue | $1.91B | $1.77B |
| Gross profit | $1.11B | $1.02B |
| R&D expense | $186.18M | $190.71M |
| SG&A expense | $526.83M | $476.44M |
| Operating income | $394.10M | $249.33M |
| Pretax income | $139.21M | -$55.01M |
| Income tax | $11.28M | $18.86M |
| Net income | $72.06M | -$116.89M |
| EBITDA | $451.40M | $311.93M |
| EPS (basic) | 0.23 | -0.38 |
| EPS (diluted) | 0.22 | -0.38 |
| Weighted avg. shares (diluted) | 324.81M | 308.98M |
| Balance sheet | ||
| Cash & equivalents | $282.03M | $118.42M |
| Inventory | $606.30M | $612.45M |
| Current assets | $1.91B | $1.59B |
| PP&E, net | $442.95M | $424.91M |
| Goodwill | $595.47M | $597.44M |
| Intangibles | $563.50M | $732.38M |
| Total assets | $3.68B | $3.50B |
| Current liabilities | $881.63M | $1.13B |
| Short-term debt | $6.76M | $224.21M |
| Long-term debt | $2.57B | $2.16B |
| Total debt | $2.57B | $2.39B |
| Total liabilities | $3.67B | $3.55B |
| Shareholders' equity | -$70.79M | -$109.27M |
| Net debt | $2.29B | $2.27B |
| Cash flow statement | ||
| Operating cash flow | $339.99M | $295.10M |
| Capital expenditure | $70.06M | $51.92M |
| Free cash flow | $269.93M | $243.18M |
| Investing cash flow | -$112.26M | -$63.00M |
| Financing cash flow | -$31.53M | -$211.79M |
| Depreciation & amortization | $57.30M | $62.60M |
| Stock-based compensation | $31.95M | $27.77M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.